SMARCC1 is altered in 0.11% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast neoplasm, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in SMARCC1 are SMARCC1 Loss (0.17%), SMARCC1 D250G (0.08%), SMARCC1-SETD2 Fusion (0.01%), SMARCC1 A322V (0.04%), and SMARCC1 A521V (0.04%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.